170 related articles for article (PubMed ID: 12087455)
1. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
O'Sullivan JM; McCready VR; Flux G; Norman AR; Buffa FM; Chittenden S; Guy M; Pomeroy K; Cook G; Gadd J; Treleaven J; Al-Deen A; Horwich A; Huddart RA; Dearnaley DP
Br J Cancer; 2002 Jun; 86(11):1715-20. PubMed ID: 12087455
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
O'Sullivan JM; Norman AR; McCready VR; Flux G; Buffa FM; Johnson B; Coffey J; Cook G; Treleaven J; Horwich A; Huddart RA; Parker CC; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1055-61. PubMed ID: 16572306
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
[TBL] [Abstract][Full Text] [Related]
4. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
5. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
van Dodewaard-de Jong JM; de Klerk JM; Bloemendal HJ; van Bezooijen BP; de Haas MJ; Wilson RH; O'Sullivan JM
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1990-8. PubMed ID: 21792569
[TBL] [Abstract][Full Text] [Related]
7. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
8. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
[TBL] [Abstract][Full Text] [Related]
9. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Graham MC; Scher HI; Liu GB; Yeh SD; Curley T; Daghighian F; Goldsmith SJ; Larson SM
Clin Cancer Res; 1999 Jun; 5(6):1307-18. PubMed ID: 10389913
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
11. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
13. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Holle LH; Humke U; Trampert L; Ziegler M; Kirsch CM; Oberhausen E
Urologe A; 1997 Nov; 36(6):540-7. PubMed ID: 9487590
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.
Palmedo H; Guhlke S; Bender H; Sartor J; Schoeneich G; Risse J; Grünwald F; Knapp FF; Biersack HJ
Eur J Nucl Med; 2000 Feb; 27(2):123-30. PubMed ID: 10755716
[TBL] [Abstract][Full Text] [Related]
16. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Liepe K; Kropp J; Hliscs R; Franke WG
Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
18. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
19. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Liepe K; Kropp J; Runge R; Kotzerke J
Br J Cancer; 2003 Aug; 89(4):625-9. PubMed ID: 12915868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]